Nephrocare Health Services Limited will attend an investor conference hosted by Bank of America on June 04, 2026, in Hyderabad. The meeting is part of the BoFA Healthcare Tour and will include both group and one-on-one sessions with institutional investors. The company confirmed that discussions will be based solely on publicly available information and no unpublished price sensitive information (UPSI) will be disclosed.

The disclosure was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Kishore Kathri, the Company Secretary & Compliance Officer, signed the intimation on May 27, 2026.

The schedule for the meeting is detailed below:

Nephrocare Health Services Limited noted that changes to the schedule may occur due to exigencies on the part of the host or the company. The information is available on the company’s official website.

Nephrocare Health Services has released the transcript of its investors' conference call regarding the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported a 32.2% increase in revenue to ₹998.8 crore for FY26, driven by a 16.6% growth in treatment volumes and a 13.3% rise in revenue per treatment. Adjusted PAT for the year surged 74.6% to ₹128.3 crore, reflecting strong operating leverage and margin expansion.

Financial Performance Overview

For the full fiscal year, revenue grew to ₹998.8 crore from ₹755.8 crore in FY25. Adjusted EBITDA increased 37.6% to ₹238.1 crore, with margins improving by 100 basis points to 23.8%. The company reported an annual pre-tax Return on Capital Employed (ROCE) of 22.8%, an improvement from 19.9% in the previous year. For Q4 FY26, revenue stood at ₹265.6 crore, a 21.2% year-on-year increase, while Adjusted PAT was ₹35 crore.

Key Financial Metrics

The following table summarises the key financial metrics for Q4 and FY26:

Operational and Strategic Highlights

Nephrocare Health Services recorded 38,44,658 dialysis sessions in FY26, a 16.6% increase over the previous year. The active guest count grew by 11.8% to 36,981. The international revenue contribution rose from 32% in FY25 to 42% in FY26, driven by expansions in the Philippines and Uzbekistan. The company continues to target a revenue CAGR of 15% to 20% over the next three to four years, supported by its asset-light model and disciplined capital allocation.